Return On Equity
-70%
Third-party reference; reporting period not verified
ABVC BIOPHARMA, INC. financial metrics
Period Q3 2026 · Filed 10 Nov 2026
Key metrics snapshot
Return On Assets
-23%
Third-party reference; reporting period not verified
Operating Margin
0%
Third-party reference; reporting period not verified
Current Ratio
0.07x
Third-party reference; reporting period not verified
Quick Ratio
0.02x
Third-party reference; reporting period not verified
Debt-to-equity
0.24x
Third-party reference; reporting period not verified
NetIncomeLoss YoY
33%
Trailing 12 months · Through 30 Sep 2026
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
-70%
Third-party reference; reporting period not verified
|
|
| Return On Assets |
-23%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
0%
Third-party reference; reporting period not verified
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.07x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
0.02x
Third-party reference; reporting period not verified
|
|
| Debt-to-equity |
0.24x
Third-party reference; reporting period not verified
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
33%
Trailing 12 months · 30 Sep 2026
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
26,976,625
Period-end balance · 09 Nov 2026
|
+11% |
| Common Stock, Shares, Outstanding |
26,841,266
Period-end balance · 30 Sep 2026
|
+11% |
| Common Stock, Value, Issued |
$26,841
Period-end balance · 30 Sep 2026
|
+11% |
| Weighted Average Number of Shares Outstanding, Basic |
26,656,942
Reported period · 30 Sep 2026
|
+15% |
| Weighted Average Number of Shares Outstanding, Diluted |
26,656,942
Reported period · 30 Sep 2026
|
+15% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
$514,802
Period-end balance · 30 Sep 2026
|
+5.7% |
| Additional Paid in Capital |
$98,567,984
Period-end balance · 30 Sep 2026
|
+5% |
| Assets |
$20,296,072
Period-end balance · 30 Sep 2026
|
-4.3% |
| Assets, Current |
$1,404,384
Period-end balance · 30 Sep 2026
|
-58% |
| Cash and Cash Equivalents, at Carrying Value |
$11,294
Period-end balance · 30 Sep 2026
|
-94% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$11,294
Period-end balance · 30 Sep 2026
|
-99% |
| Common Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 30 Sep 2026
|
0% |
| Common Stock, Shares Authorized |
100,000,000
Period-end balance · 30 Sep 2026
|
0% |
| Common Stock, Shares, Issued |
26,841,266
Period-end balance · 30 Sep 2026
|
+11% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
-$3,887,116
Trailing 12 months · 30 Sep 2026
|
+34% |
| Contract with Customer, Liability, Current |
$12,600
Period-end balance · 30 Sep 2026
|
-84% |
| Deferred Tax Assets, Gross |
$7,819,188
Period-end balance · 30 Sep 2026
|
+13% |
| Deferred Tax Assets, Operating Loss Carryforwards |
$6,932,495
Period-end balance · 30 Sep 2026
|
+16% |
| Deferred Tax Assets, Valuation Allowance |
$7,819,188
Period-end balance · 30 Sep 2026
|
+13% |
| Earnings Per Share, Basic |
-0.16
Trailing 12 months · 30 Sep 2026
|
+47% |
| Earnings Per Share, Diluted |
-0.16
Trailing 12 months · 30 Sep 2026
|
+47% |
| Employee-related Liabilities, Current |
$15,559
Period-end balance · 30 Sep 2026
|
-90% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
-$6,907,013
Trailing 12 months · 30 Sep 2026
|
-13% |
| Lessee, Operating Lease, Liability, to be Paid |
$1,954,141
Period-end balance · 30 Sep 2026
|
+416% |
| Lessee, Operating Lease, Liability, to be Paid, Year Four |
$422,821
Period-end balance · 30 Sep 2026
|
+731% |
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$442,270
Period-end balance · 30 Sep 2026
|
+273% |
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$459,222
Period-end balance · 30 Sep 2026
|
+802% |
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$447,266
Period-end balance · 30 Sep 2026
|
+704% |
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$272,140
Period-end balance · 30 Sep 2026
|
+2818% |
| Liabilities |
$8,554,428
Period-end balance · 30 Sep 2026
|
+27% |
| Liabilities and Equity |
$20,296,072
Period-end balance · 30 Sep 2026
|
-4.3% |
| Liabilities, Current |
$7,192,554
Period-end balance · 30 Sep 2026
|
+9.9% |
| Nonoperating Income (Expense) |
-$1,115,511
Trailing 12 months · 30 Sep 2026
|
-134% |
| Operating Income (Loss) |
-$5,791,502
Trailing 12 months · 30 Sep 2026
|
-2.4% |
| Operating Lease, Liability |
$1,682,001
Period-end balance · 30 Sep 2026
|
+356% |
| Operating Lease, Liability, Current |
$338,794
Period-end balance · 30 Sep 2026
|
+70% |
| Operating Lease, Liability, Noncurrent |
$1,343,207
Period-end balance · 30 Sep 2026
|
+719% |
| Operating Lease, Payments |
$21,231
Trailing 12 months · 30 Sep 2026
|
+59% |
| Operating Lease, Right-of-Use Asset |
$1,658,963
Period-end balance · 30 Sep 2026
|
+349% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.0724
Period-end balance · 30 Sep 2026
|
+182% |
| Other Assets, Noncurrent |
$106,682
Period-end balance · 30 Sep 2026
|
-8.8% |
| Preferred Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 30 Sep 2026
|
0% |
| Preferred Stock, Shares Authorized |
20,000,000
Period-end balance · 30 Sep 2026
|
0% |
| Property, Plant and Equipment, Gross |
$16,220,275
Period-end balance · 30 Sep 2026
|
-0.11% |
| Property, Plant and Equipment, Net |
$12,825,164
Period-end balance · 30 Sep 2026
|
-0.22% |
| Research and Development Expense |
$102,905
Trailing 12 months · 30 Sep 2026
|
-17% |
| Retained Earnings (Accumulated Deficit) |
-$77,254,088
Period-end balance · 30 Sep 2026
|
-4.3% |
| Share-based Payment Arrangement, Expense |
$791,980
Trailing 12 months · 30 Sep 2026
|
-79% |
| Share-based Payment Arrangement, Noncash Expense |
$3,272,235
Trailing 12 months · 30 Sep 2026
|
+4.9% |
| Stockholders' Equity Attributable to Parent |
$13,050,848
Period-end balance · 30 Sep 2026
|
+8.2% |
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
$11,741,644
Period-end balance · 30 Sep 2026
|
-19% |
Comparisons, sources and research notes
Sources and sharing
ABVC - ABVC BIOPHARMA, INC. Financial Facts
- Context
- Latest metrics period: Q3 2026
- Latest reported value
- Return On Equity -70%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2026.
- Most recent SEC facts end date on this page: 09 Nov 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for ABVC - ABVC BIOPHARMA, INC.
Latest financial period: Q3 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
10 Nov 2026
Page type
Company facts
Latest period
Q3 2026
SEC-backed company facts were refreshed from filings filed on 10 Nov 2026.
Benchmark Context
How Return On Equity compares
Return On Equity does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with ABVC BIOPHARMA, INC.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2026.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- ABVC - ABVC BIOPHARMA, INC. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2026.
- Headline metric: Return On Equity -70%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 09 Nov 2026.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-11-09) highlights Return On Equity -69.9%, Return On Assets -22.9%, and Operating Margin 0.0%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -2,165,149.0 USD · through 2026-09-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Capital expenditures: unavailable on a verified comparable basis
- Cash and equivalents: 11,294.0 USD · through 2026-09-30 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Free cash flow unavailable: matching usd annual or trailing-12-month operating cash flow and cash capex are required
- Debt unavailable: no complete usd debt balance at the latest balance date
- Valuation unavailable: free cash flow is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare ABVC - ABVC BIOPHARMA, INC. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: 33%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
30.1/100
Weak Confidence medium
Return On Equity
-70%
Metric score 0.0/100
Return On Assets
-23%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.07x
- Quick Ratio
- 0.02x
- Debt to Equity
- 0.24x
Strengths
Debt-to-equity and NetIncomeLoss YoY
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first